Title: Rethinking Routine Intensive Care After Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy: The Fiscal Argument.

Authors: Schwartz, Patrick B; Stahl, Christopher C; Vidri, Roberto J; Leverson, Glen E; Puckett, Yana; Zafar, Syed N; Varley, Patrick; Ronnekleiv-Kelly, Sean M; Al-Niaimi, Ahmed; Weber, Sharon M; Abbott, Daniel E

Published In Ann Surg Oncol, (2022 Oct)

Abstract: BACKGROUND: Patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) are frequently admitted to the intensive care unit (ICU) for mitigation of potential complications, although ICU length of stay (LOS) is a significant driver of cost. This study asked whether a fiscal argument could be made for the selective avoidance of ICU admission after CRS/HIPEC. METHODS: Prospective data for select low-risk patients (e.g., lower peritoneal cancer index [PCI]) admitted to the intermediate care unit (IMC) instead of the ICU after CRS/HIPEC were matched with a historic cohort routinely admitted to the ICU. Cohort comparisons and the impact of the intervention on cost were assessed. RESULTS: The study matched 81 CRS/HIPEC procedures to form a cohort of 49 pre- and 15 post-intervention procedures for patients with similar disease burdens (mean PCI, 8 ± 6.7 vs. 7 ± 5.1). The pre-intervention patients stayed a median of 1 day longer in the ICU (1 day [IQR, 1-1 day] vs. 0 days [IQR, 0-0 days]) and had a longer LOS (8 days [IQR, 7-11 days] vs. 6 days [IQR, 5.5-9 days]). Complications and complication severity did not differ statistically. The median total hospital cost was lower after intervention ($30,845 [IQR, $30,181-$37,725] vs. $41,477 [IQR, $33,303-$51,838]), driven by decreased indirect fixed cost ($8984 [IQR, $8643-$11,286] vs. $14,314 [IQR, $12,206-$18,266]). In a weighted multiple variable linear regression analysis, the intervention was associated with a savings of $2208.68 per patient. CONCLUSIONS: Selective admission to the IMC after CRS/HIPEC was associated with $2208.68 in savings per patient without added risk. In this era of cost-conscious practice of medicine, these data highlight an opportunity to decrease cost by more than 5% for patients undergoing CRS/HIPEC.

PubMed ID: 35672624

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Critical Care; Cytoreduction Surgical Procedures/adverse effects; Humans; Hyperthermia, Induced*/adverse effects; Percutaneous Coronary Intervention*; Peritoneal Neoplasms*/etiology; Peritoneal Neoplasms*/therapy; Prospective Studies; Retrospective Studies; Survival Rate